Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,687.00
Bid: 4,686.00
Ask: 4,690.00
Change: -39.00 (-0.83%)
Spread: 4.00 (0.085%)
Open: 4,691.00
High: 4,719.00
Low: 4,673.00
Prev. Close: 4,726.00
CRDA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Jez Maiden to retire as Group Finance Director

7 Nov 2022 07:00

RNS Number : 4466F
Croda International PLC
07 November 2022
 

Croda International Plc

 

Jez Maiden to retire as Group Finance Director;

Louisa Burdett appointed as successor

 

7 November 2022

 

Croda International Plc ("Croda" or "the Company") announces that Jez Maiden, Group Finance Director, has advised the Board that he will be retiring from the Company during 2023 after eight years in the role. The Board has appointed Louisa Burdett, until recently Chief Financial Officer ("CFO") of Meggitt Plc ("Meggitt"), the global aerospace, defence and energy component manufacturer, to succeed Jez.

 

Jez joined Croda in January 2015, subsequently transforming the Finance, IT and Digital functions, and developing a broad, diverse pool of talent. He has modernised Croda's processes, introduced new standards of operational excellence and financial reporting, and closely supported the Chief Executive in the development and deployment of Croda's strategy. Jez led the creation of Croda's sustainability metrics, as well as its approach to capital allocation, which has underpinned shareholder value creation by enabling investment in organic growth, targeted acquisitions and strong returns. He also co-led the successful separation of the majority of Croda's Performance Technology and Industrial Chemicals businesses, accelerating the Company's transition to be a pure-play Consumer Care and Life Sciences business.

 

Louisa has over ten years of experience successfully leading finance functions for UK listed companies. This includes four years as CFO of Meggitt, before it was acquired by Parker-Hannifin in September 2022, and five years as CFO of Victrex, the speciality chemicals company. Prior to that she held CFO positions with Optos plc, Financial Times Group, GE Healthcare, and CHEP Europe. Louisa is also Non-executive Director and Audit Committee Chair of RS Group Plc, the FTSE 100 distributor of industrial and electronic products. She has a first-class degree in biochemistry from Imperial College London and trained as an accountant before moving into her first in-house role at GSK.

 

To enable a smooth transition, Louisa will join Croda and the Board on 1 January 2023. She will succeed Jez as Group Finance Director on 13 March 2023, following Croda's 2022 Full Year results at the end of February. Jez will step down from the Board at the Annual General Meeting on 26 April 2023 and retire from the Company on 31 May 2023.

 

Commenting, Anita Frew, Croda Chair said: 

"On behalf of the Board and all my Croda colleagues, I would like to thank Jez for his outstanding contribution over the last eight years. He has been instrumental in the development and growth of Croda, always nurturing a culture of transformation. I have hugely appreciated his diligence, intellect and thoughtful approach, particularly his contribution to Board debate, and wish him the very best wishes for the future.

 

"I am delighted that we have been able to appoint Louisa as Group Finance Director. She has an exceptional ten-year track record as a CFO of listed companies, with valuable experience both in speciality chemicals and the broader manufacturing sector. We look forward to welcoming Louisa to Croda in the New Year."

 

There are no further details required to be disclosed under LR 9.6.13R of the Listing Rules of the UK Listing Authority.

-ENDS-

 

For enquiries contact:

Investors:

David Bishop, Croda

+44 7823 874428

Reece De Gruchy, Croda

+44 7826 548908

Press:

Charlie Armitstead, Teneo

+44 7703 330269

 

About Croda - www.croda.com

Established in 1925, Croda is the name behind sustainable, high-performance ingredients and technologies in some of the world's most successful brands: creating, making and selling speciality chemicals that are relied on by industries and consumers everywhere.

Croda is a FTSE 100 company with over 5,500 passionate and innovative employees, working across manufacturing sites and offices around the world with a shared Purpose to use Smart science to improve lives™. As part of this Purpose, Croda has committed to be the most sustainable supplier of innovative ingredients, becoming Climate, Land and People Positive by 2030. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAKZLFBLFLBFBD
Date   Source Headline
7th Oct 20227:59 amRNSDirector/PDMR Shareholding
7th Oct 20227:00 amRNSInvestor seminar
5th Oct 20224:42 pmRNSDirector/PDMR Shareholding
20th Sep 20229:01 amRNSDirector/PDMR Shareholding
13th Sep 20221:47 pmRNSDirector/PDMR Shareholding
11th Aug 20222:39 pmRNSDirector/PDMR Shareholding
29th Jul 20227:00 amRNSResults for the six months ended 30 June 2022
22nd Jul 20224:50 pmRNSDirectorate Change
12th Jul 20223:08 pmRNSDirector/PDMR Shareholding
1st Jul 20227:00 amRNSCompleted divestment
30th Jun 202212:15 pmRNSTotal Voting Rights
28th Jun 20227:00 amRNSUS Government to support lipid systems expansion
22nd Jun 20229:07 amRNSHolding(s) in Company
17th Jun 20229:46 amRNSHolding(s) in Company
13th Jun 20222:52 pmRNSDirector/PDMR Shareholding
8th Jun 202211:53 amRNSDirector/PDMR Shareholding
7th Jun 20225:23 pmRNSTransaction in Own Shares
7th Jun 20224:08 pmRNSDirector/PDMR Shareholding
7th Jun 20223:27 pmRNSHolding(s) in Company
27th May 202210:48 amRNSHolding(s) in Company
26th May 20227:02 amRNSDirector Declaration
23rd May 20222:34 pmRNSResult of AGM
20th May 20227:21 amRNSAGM trading update
19th May 20223:09 pmRNSDirector/PDMR Shareholding
19th May 20222:17 pmRNSHolding(s) in Company
11th May 20222:15 pmRNSDirector/PDMR Shareholding
11th May 20227:00 amRNSSite visit and investor presentation
3rd May 202210:21 amRNSDirector/PDMR Shareholding
13th Apr 20229:48 amRNSDirector/PDMR Shareholding
7th Apr 20226:15 pmRNSDirector/PDMR Shareholding
31st Mar 20223:12 pmRNSUK Government to support lipid systems expansion
29th Mar 20227:00 amRNSInvestor seminar
22nd Mar 20226:14 pmRNSAnnual Financial Report
22nd Mar 20224:49 pmRNSDirector/PDMR Shareholding
16th Mar 20225:21 pmRNSDirector/PDMR Shareholding
16th Mar 20225:20 pmRNSDirector/PDMR Shareholding
16th Mar 20225:19 pmRNSDirector/PDMR Shareholding
16th Mar 20225:15 pmRNSDirector/PDMR Shareholding
16th Mar 20225:15 pmRNSDirector/PDMR Shareholding
16th Mar 20225:13 pmRNSDirector/PDMR Shareholding
16th Mar 20225:11 pmRNSDirector/PDMR Shareholding
16th Mar 20225:11 pmRNSDirector/PDMR Shareholding
16th Mar 20225:04 pmRNSDirector/PDMR Shareholding
16th Mar 20225:03 pmRNSDirector/PDMR Shareholding
15th Mar 202211:24 amRNSDirector/PDMR Shareholding
11th Mar 20222:25 pmRNSDirector/PDMR Shareholding
10th Mar 20221:10 pmRNSDirector/PDMR Shareholding
3rd Mar 202211:27 amRNSDirector/PDMR Shareholding
1st Mar 20227:00 amRNSResults for the year ended 31 December 2021
11th Feb 20222:26 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.